BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31180306)

  • 1. Validation of dominant and secondary sequence utilization in PI-RADS v2 for classifying prostatic lesions.
    Soodana-Prakash N; Castillo RP; Reis IM; Stoyanova R; Kwon D; Velasquez MC; Nahar B; Kannabur P; Johnson TA; Swain SK; Ben-Yakar N; Venkatramani V; Ritch C; Satyanarayana R; Gonzalgo ML; Parekh DJ; Bittencourt L; Punnen S
    Can J Urol; 2019 Jun; 26(3):9763-9768. PubMed ID: 31180306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 3. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
    Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
    Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
    Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
    AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
    [No Abstract]   [Full Text] [Related]  

  • 5. Interobserver Agreement and Positivity of PI-RADS Version 2 Among Radiologists with Different Levels of Experience.
    Mussi TC; Yamauchi FI; Tridente CF; Tachibana A; Tonso VM; Recchimuzzi DR; de Souza Leão LR; Luz DC; Martins T; Baroni RH
    Acad Radiol; 2019 Aug; 26(8):1017-1022. PubMed ID: 30268722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.
    Feng ZY; Wang L; Min XD; Wang SG; Wang GP; Cai J
    Chin Med J (Engl); 2016 Oct; 129(20):2451-2459. PubMed ID: 27748338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
    Chen F; Cen S; Palmer S
    Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
    Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
    AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
    Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
    Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1.
    Linhares Moreira AS; De Visschere P; Van Praet C; Villeirs G
    Acta Radiol; 2021 Jun; 62(6):839-847. PubMed ID: 32702998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion-targeted biopsy in patients with a solitary PI-RADS v2-scored lesion.
    Syed JS; Nguyen KA; Nawaf CB; Bhagat AM; Huber S; Levi A; Humphrey P; Weinreb JC; Schulam PG; Sprenkle PC
    Urol Oncol; 2017 Sep; 35(9):542.e19-542.e24. PubMed ID: 28501565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of PI-RADS v2 and PI-RADS v1.
    Polanec S; Helbich TH; Bickel H; Pinker-Domenig K; Georg D; Shariat SF; Aulitzky W; Susani M; Baltzer PA
    Eur J Radiol; 2016 Jun; 85(6):1125-31. PubMed ID: 27161062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
    Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
    Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
    Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
    World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inter-Reader Variability Using PI-RADS v2 Versus PI-RADS v2.1: Most New Disagreement Stems from Scores 1 and 2.
    Beetz NL; Haas M; Baur A; Konietschke F; Roy A; Hamm CA; Rudolph MM; Shnayien S; Hamm B; Cash H; Asbach P; Penzkofer T
    Rofo; 2022 Aug; 194(8):852-861. PubMed ID: 35545106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.